Eli Lilly's GLP-1 and metabolic franchise can compound demand and cash flows while rate fears punish leveraged AI stories. It is preferable as a defensive-growth holding into its October 29 earnings over chasing a chip bounce. Continued healthcare volume leadership would support the sleeve; if semiconductors reclaim leadership first, the rotation is already crowded the other way. x.com  x.com 

Eli Lilly earns its place in a portfolio with a defensive profile plus tech-like growth rates, a strength that stands out on a down day for the market. An IBD MarketSurge chart accompanies the point. x.com 

Security software is arguably more of an AI bubble than semiconductors. Firms are bid up to nosebleed multiples on moderate AI-related revenue acceleration while facing medium- to long-term risks from Microsoft, Google and the AI labs and a 10-year Treasury yield above 5%. Their forward P/Es rest on non-GAAP earnings that exclude large stock compensation. A reversal could come from results missing high buy-side bars, security share gains by Microsoft or Google, or AI lab security launches. x.com  … Show more

Ten proven non-tech businesses with durable advantages and long compounding records can beat the S&P 500 over five years at lower risk. Eli Lilly has huge diabetes and obesity franchises; Costco has membership revenue and loyalty; Walmart adds higher-margin e-commerce and ads; JPMorgan is arguably the strongest US bank; Caterpillar and Brookfield ride infrastructure and AI capital needs; O'Reilly and AutoZone pair steady earnings with buybacks; American Express and Berkshire compound reliably. … Show more

Eli Lilly at new record highs still trades at only 26x forward earnings despite 55% revenue growth and triple-digit EPS growth last quarter. EPS is projected to grow 51% this year. x.com 

AI's application layer remains the long-term bet: after 24 months in infrastructure on obvious earnings, capital must now move to the layer that produces durable economic value. Tempus AI's edge is proprietary data, which stays scarce as raw intelligence gets cheaper. Eli Lilly's LillyPod pairs 1,000 Blackwell GPUs with decades of clinical data, an underrated moat. Lemonade's tech yields cost, price and growth edges. Coinbase provides the stablecoin financial guardrails agentic AI needs. x.com 

Eli Lilly is well positioned for an AI-driven biotech boom, and strong Q2 results back that up. Revenue reached $22.97B against $20.59B expected, with Zepbound at $4.93B and Mounjaro at $9.9B both ahead of estimates. Lilly raised full-year revenue guidance to $85-87B from $82-85B and committed an additional $4.5B to expand manufacturing. x.com  x.com 

Most portfolios are heavily concentrated in AI stocks, and these twelve high-quality companies could offer diversification: Mastercard, Visa, Eli Lilly, JPMorgan, MercadoLibre, Celsius, Netflix, Exelixis, First Solar, Zoetis, Airbnb and Hims & Hers. x.com  x.com  x.com  x.com  x.com  x.com  x.com  x.com  x.com  x.com  x.com  x.com 

Cybersecurity is the one software subsector where AI strengthens the story, because every AI gain arms both attackers and defenders, so spending only ratchets up. The market is forecast to grow from $189 billion in 2024 to $402 billion by 2034. Palo Alto sells consolidation: revenue grew 31% last quarter, and once customers platformize, switching costs become a fortress. Fortinet and Palo Alto rank first and second among software names in an 811-stock screen driven by institutional buying. x.com  … Show more

Eli Lilly is reasonably valued, not priced for perfection, given its growth and pipeline. @janthecurious1 argues that retatrutide's TRIUMPH-2 tolerability, including 33.6% diarrhea and 11.6% discontinuation at 9 mg, puts Lilly's roughly 28x forward P/E against Novo Nordisk's 12x in question. Novo Nordisk, by contrast, is priced for bankruptcy and needs good news and a return to growth. x.com